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Abstract
Background: Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected
patients. Our study aims at identifying the correlates of access to HCV treatment in this population.
Methods: We used 3-year follow-up data from the HEPAVIH ANRS-CO13 nationwide French cohort which enrolled
patients living with HIV and HCV. We included pegylated interferon and ribavirin-naive patients (N = 600) at
enrolment. Clinical/biological data were retrieved from medical records. Self-administered questionnaires were used
for both physicians and their patients to collect data about experience and behaviors, respectively.
Results: Median [IQR] follow-up was 12[12-24] months and 124 patients (20.7%) had started HCV treatment. After
multiple adjustment including patients’ negative beliefs about HCV treatment, those followed up by a general
practitioner working in a hospital setting were more likely to receive HCV treatment (OR[95%CI]: 1.71 [1.06-2.75]).
Patients followed by general practitioners also reported significantly higher levels of alcohol use, severe depressive
symptoms and poor social conditions than those followed up by other physicians.
Conclusions: Hospital-general practitioner networks can play a crucial role in engaging patients who are the most
vulnerable and in reducing existing inequities in access to HCV care. Further operational research is needed to
assess to what extent these models can be implemented in other settings and for patients who bear the burden
of multiple co-morbidities.
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Background
Liver fibrosis progresses faster in HIV-HCV co-infected
patients than among those with HCV alone [1]. While
AIDS mortality has decreased sharply since the wide-
spread introduction of antiretroviral treatment (ART) in
1996, end stage liver diseases now represent one of the
leading causes of death in this population [2-5].
Treatment for HCV is available and cost-effective [6];
it cures 45% of patients with HCV genotype 1 infection
and 75% of those with HCV genotype 2 or genotype 3
infection [7-9]. The current recommendations for the
treatment of hepatitis C in mono-infected and HIV-
HCV co-infected patients are much more liberal than
before [10,11]. Previous indications which tended to
delay or deny HCV treatment such as existing illicit
drug/alcohol abuse, chronic renal disease, having under-
gone a liver transplant and severe psychiatric disease, no
longer preclude patients from initiating treatment if ade-
quate patient monitoring is ensured during follow-up.
Rate estimates of treatment uptake in mono-infected
HCV patients may vary considerably [12-19]. Most are
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from 3% to 28% [12,20-23].
Patient characteristics, such as age, genotype, hepatic
dysfunction, substance abuse, mental health issues and
perception about treatment effectiveness and side effects
[17,24] are important predictors of HCV treatment
initiation. However, a significant proportion of variation
in treatment uptake is explained by both structural fac-
tors (including those related to the experience of provi-
d e r s[ 1 9 ]a n dt h em o d e lo fc a r eu s e dt oe n g a g em o s t
excluded populations [25-27]) and patient social bar-
riers, such as financial difficulties [14].
In HIV-HCV co-infected patients, HCV treatment
uptake rates are usually lower than 50% and vary across
the different regions of Europe [28,29]. In a large Eur-
opean survey published in 2006, the rate of treatment
uptake was lower than 30%. In France, one cross-sec-
tional study showed that 46% of HIV-HCV co-infected
patients followed up in specialized centers for HIV care
had received HCV treatment in 2004 [30] while other
studies confirmed that barriers are found when engaging
HIV-HCV co-infected individuals in HCV care [31,32].
In this population, several factors, not only those
linked to HIV or HCV infections, might play a role in
treatment uptake. It has been shown for example that
isolation, lack of social support and legal issues are
related to HCV treatment initiation [33] and that drug
use and opioid dependence are conditions limiting not
only access to liver biopsy [34,35] but also referral for
[36,37] and initiation of HCV treatment [38]. It has also
been consistently shown that opioid maintenance treat-
ment facilitates HCV treatment initiation [39], especially
in the case of one-site models of care.
Moreover, patient beliefs (such as fears of adverse
effects of treatment or the conviction that treatment is
ineffective) could also negatively influence uptake of
HCV treatment.
It is worthwhile noting that HIV-HCV co-infection is
a severe medical condition that requires a thorough eva-
luation of liver fibrosis and HIV status before starting
HCV treatment. For these reasons HIV-HCV treatment
is mainly initiated in hospitals. Though care for both
diseases is free in France, some of the most vulnerable
populations have less access to hospital services, and are
more likely to attend primary care or non-referral
clinics. However, in France, many non-specialized physi-
cians, particularly those engaged in primary care for vul-
nerable populations like drug users or HIV-infected
individuals, are members of or adhere to specialized net-
works. These networks are created solely on the initia-
tive of local health care professionals engaged in
improving access and quality of health care in a multi-
disciplinary manner. These networks may work in differ-
ent ways and do not have a standardized structure
unlike in other countries [25]; however there are some
characteristics in common. They are all partially funded
by the government; GPs belonging to a network do not
work in the same hospital or health care setting but can
divide their activity between their private office and hos-
pital. Members of the network meet once per month to
receive specific training and medical management
update, including HIV and HCV clinical management.
In 2006, a large national cohort of HIV/HCV infected
patients was implemented in France (ANRS CO13-
HEPAVIH, N = 1040) and entailed the yearly collection
of clinical and socio-behavioral data [40]. We used 3-
year follow-up data from the HEPAVIH ANRS-CO13
nationwide French cohort to study the extent to which
the characteristics of patients and physicians, may play a
role in improving access to HCV treatment for HIV-
HCV co-infected individuals.
Methods
Study design
In 2006, a nationwide prospective cohort study, ANRS
CO 13 HEPAVIH, was initiated in 17 infectious diseases
outpatient clinics delivering care to HIV-HCV co-
infected patients in France.
Consecutive patients seen in 17 hospital wards
between January 2006 and December 2008 and fulfilling
the following criteria were enrolled in the cohort: aged
18 years or more, chronically infected with HIV and
HCV as confirmed by a positive HIV antibody test and
an HCV RNA assay (regardless of the clinical stage, gen-
der and transmission group), and finally, provided writ-
ten informed consent [40].
The study was approved by the Institutional Review
Board of Cochin Hospital (Paris).
Clinical and biological data, including HIV RNA
plasma viral load, CD4 cell count and the degree of liver
fibrosis, together with data on HCV treatment initiation,
were collected from a clinical research form completed
by medical staff in outpatient hospital services. This
form also contained information about HCV genotype,
diagnosis of cirrhosis, Alanine AminoTransferase (ALT)
level, Aspartate AminoTransferase (AST) level, HCV
plasma viral load, previous HCV treatment, HIV antire-
troviral treatment, and finally comorbidities (diabetes,
hypertension, cardiovascular problems, renal dysfunction
etc.)
Liver biopsy was performed at enrolment when possi-
ble. The results were documented and graded according
to the Metavir system, measuring the activity of chronic
hepatitis (none, minimal, moderate, severe) and the
severity of fibrosis (none, portal fibrosis, portal fibrosis
with rare septa, bridging fibrosis, cirrhosis). Whenever
possible, a systematic assessment of liver fibrosis was
also performed using two non-invasive methods: the
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FibroScan™ Ultrasound examination was performed to
screen for possible complications of liver disease. In the
case of suspected or diagnosed cirrhosis, an endoscopic
examination was prescribed. The schedule of follow-up
visits was based on clinical practice as recommended by
consensus conferences on hepatitis C, which are held
every six months and every year for cirrhotic and for
non-cirrhotic patients, respectively. Severe fibrosis
(Metavir Score F ≥ 3) was assessed using an algorithm
which took into account either liver biopsy, if performed
less than one year before the visit or if not and the pre-
sence of indirect clinical signs of cirrhosis (oesophageal
varices, ascites, liver encephalopathy or digestive bleed-
ing) or results from non-invasive tests elastometry
(Fibroscan
®). The Fibroscan cut-off points used for
Metavir score conversion were as follows: F0-F1: < 7.1
Kpa, F2: 7.1-9.5 Kpa, F3: 9.5-12.5 Kpa, F4: ≥ 12.5. Kpa
[41].
Patient and physician self-administered questionnaires
The patient self-administered questionnaire at baseline
included items on socio-demographic characteristics
(gender, age, having a secondary school certificate, hav-
ing children, the desire for a child, living in a couple,
employment and housing conditions), psychiatric disor-
ders, addictive behaviors (depressive symptoms, alcohol
consumption, cannabis, cocaine, heroin and tobacco
use) and antidepressant treatment. It also included
items on patient beliefs about the effectiveness and toxi-
city of HCV treatment, measured on a 4-point visual
analogue scale.
A new variable was also built contrasting individuals
who perceived treatment effectiveness as poor (score 1)
and those who perceived treatment as highly toxic
(score 4) with the rest of the study population.
Patient depressive symptoms were assessed using the
Center for Epidemiological Studies Depression Ques-
tionnaire (CES-D) [42] which provides a global depres-
sion score ranging from 0 to 60, with gender-specific
cut-off values (17 for men and 23 for women (18)).
Score values above these cut-off points were taken as
indicative of depressive symptoms. The 75% percentile
of CES-D score (CES-D = 25) was also used to identify
individuals with severe depressive symptoms.
A section of the self-administered questionnaire, based
on the Symptoms Distress Module proposed by Justice
et al. [43], also collected data about the occurrence of
39 treatment-related symptoms (defined here as self-
reported side effects) over the previous four weeks, and
the discomfort they caused. It was broadened to include
questions on lipodystrophy symptoms. In the self-admi-
nistered questionnaire, alcohol consumption was
assessed by AUDIT-C [44,45] with three questions
designed to compute the number of drinks per day. A
standard drink containing 11-14 g of alcohol corre-
sponds to one alcohol unit (AU). Women and men who
reported drinking 2 and 3 AU or more per day respec-
tively [46] were considered to have harmful alcohol con-
sumption. Heroin, cocaine and cannabis use referred to
the 4 weeks prior to the visit when the self-administered
questionnaire was proposed.
Physicians who enrolled patients in the study and
were the primary physician involved in HIV-HCV fol-
low-up of patients included in the cohort were provided
with a self-administered physician questionnaire at the
enrolment visit and at scheduled annual visits. This
questionnaire collected data about patient socio-beha-
vioral characteristics, physicians’ experience with and
perceptions of their patients as well as information
about their patients concerning depression, alcohol use
and history of suicide attempts. Two structural hospital-
specific variables were built: the number of patients
enrolled in the cohort in each hospital and the propor-
tion of patients in each center followed up by a general
practitioner.
Outcome and study subjects
The outcome variable was the initiation of HCV treat-
ment, defined as the first prescription of pegylated inter-
feron and ribavirin, during the first three years of the
cohort follow-up.
In order to study the impact of physician and patient
clinical and socio-behavioral characteristics at enrolment
associated with initiation of HCV treatment, the analysis
was restricted to those patients having chronic hepatitis
C (defined by having a positive HCV RNA), who were
peg-IFN + Ribavirine naive at enrolment in the cohort.
Among this population, individuals with decompensated
cirrhosis or hepatocellular carcinoma who had under-
gone transplantation were excluded. In addition, patients
who had not completed any part of the self-adminis-
tered questionnaire at enrolment were also excluded.
Statistical methods
A multiple imputation approach was used for variables
presenting less than 10% missing data to obtain more
precise estimates. We used the Multivariate Imputation
by Chained Equations method [47] with m = 5 multiple
imputations, and with logistic regression and predictive
mean matching imputation models respectively for bin-
ary and continuous variables. Scores (for example the
CES-D score) were recalculated after the imputation
step.
Clinical and biological data, as well as data from the
patient self-administered questionnaires, were compared
between patients who had already started HCV treat-
ment during the first three years of the cohort follow-up
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2 or
Fisher tests were used, when appropriate, to compare
patient characteristics. Odds ratios (OR) and their 95%
confidence intervals were calculated to quantify the
strength of association between the outcome and the
correlates. As the duration of patient follow-up was
short and enrolment characteristics were tested as pre-
dictors of subsequent initiation of HCV treatment, a
logistic regression model was performed to determine
factors associated with initiation of HCV treatment.
Variables with a liberal p value < 0.20 in the univariate
analysis were considered eligible for the multivariate
model which was built using a backward procedure
based on the log-likelihood ratio test. All the analyses
were performed using Stata 10.0.
Mixed logistic regression models were also used to
verify whether the specialty of the physicians was asso-
ciated with specific characteristics of patients while
accounting for inter-variability between hospital centers,
these latter being considered as a random effect.
Results
Selection of the study sample
From the initial data set (N = 1040 of patients with
chronic hepatic C), 779 patients were peg-IFN and riba-
virin naive. The following patients were not included in
analyses: individuals with decompensated cirrhosis (N =
14), those who had undergone a liver transplantation (N
= 1) or who had hepatocellular carcinoma (N = 2) and
those who had not completed any part of the self-admi-
nistered questionnaire at enrolment (N = 162). In the
e n d ,6 0 0i n d i v i d u a l sw e r ee l i g i b l ef o rt h ep r e s e n t
analysis.
No significant differences were found in terms of gen-
der, age, CD4, HIV viral load and HCV viral load,
ASAT, ALAT, HCV genotype and fibrosis at baseline,
whether follow-up by a general practitioner or not,
between those who filled in the self-administered ques-
tionnaires (N = 600) and those who did not (N = 162).
Characteristics of the study sample
Table 1 lists the characteristics of the study sample (N =
600). Median [IQR] age was 44[41-47] years, men
accounted for 68% and most patients (63%) were HIV-
infected through injecting drug use (IDU). At enrolment
59% of the patients had undetectable plasma HIV RNA
and median CD4 cell count/mm
3 was 441[295-650].
Twenty percent had HCV genotype 2 or 3 while 67%
had genotype 1 or 4. Among the study sample, 21% pre-
sented with liver cirrhosis at enrolment and 12% had a
CD4 count < 200/mm
3. Nine percent had already been
exposed to a HCV treatment different from PEG-IFN +
ribavirin. Most patients (89%) were receiving ART at
enrolment in the cohort. The median [IQR] number of
self-reported side effects and self-reported side effects
causing discomfort were 7[2-14] and 2[0-7] respectively.
Among the study population, 49% of the study patients
were mainly followed up by an infectious disease specia-
list, 26% by a general practitioner, 15% by an internal
medicine physician, 5% by hepatologists and the remain-
ing 5% by other specialists (Figure 1).
The median [IQR] percentage of patients followed up
by general practitioners was 6% [0%-35%] while the
median [IQR] number of patients enrolled in each hos-
pital center was 27[15- 60].
Among the 600 patients followed up for a median of
12 months [12-24], 124 (20.7%) started HCV treatment
during follow-up, corresponding to an HCV treatment
incidence of 15 new events per 100 person-years. The
proportion of severe liver fibrosis was respectively 45%
and 22% for those initiating HCV treatment or not (p <
0.01, Table 1 Evaluation of liver fibrosis at enrolment (+
- one year), with liver biopsy, FibroTest™ or FibroS-
can™ was available for 209, 60 and 315 patients respec-
tively. Among patients classified as F3-F4, 40% of those
diagnosed by liver biopsy and 24% of those diagnosed
with non invasive methods (p < 10-3). started HCV
treatment during follow-up.
Table 2 shows the results of the analyses identifying
factors associated with HCV treatment initiation. In the
univariate analyses, patients were more likely to receive
treatment if they had severe fibrosis (OR [95%CI]: 2.66
[1.74-4.09]) and had had liver biopsy (OR [95% CI]: 2.31
[1.54-3.45]). Individuals who initiated HCV treatment
were more likely to be men, to be younger, to have no
children and to have been HIV or HCV diagnosed more
recently. Individuals followed-up by a general practi-
tioner working in hospital outpatient services were more
likely to receive HCV treatment whereas those reporting
negative perceptions about HCV treatment effectiveness
and toxicity initiated HCV treatment significantly less
frequently. In this study population, HIV immuno-sup-
pression and virological status were not found to be
associated with treatment initiation. After adjustment
for age (AOR [95%CI]: 0.69[0.48-0.98]), number of years
since HCV diagnosis (AOR [95%CI]: 0.69[0.49-0.97]),
having had a liver biopsy (AOR [95%CI]: 2.20[1.44-
3.35]), both severe fibrosis (AOR [95%CI]: 2.87[1.83-
4.51]) and being followed up in hospital by a general
practitioner (AOR [95%CI]: 1.71[1.06-2.75]) remained
significantly associated with an increased likelihood of
HCV treatment initiation. By contrast, patients with
negative beliefs about both HCV treatment effectiveness
and toxicity were less likely to receive HCV treatment
(AOR [95%CI]: 0.58 [0.37-0.92]).
In the final model, when the variable “f o l l o w e du pb y
a general practitioner” was replaced with the aggregated
variable “proportion of patients followed up by a
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Page 4 of 11Table 1 Characteristics of patients (N = 600) according to HCV treatment initiation during follow-up (ANRS CO13
HEPAVIH cohort.)
HCV treatment initiation
NO
% or median
[IQR]
N = 476
Yes
% or median
[IQR]
N = 124
Total
sample
% or median
[IQR]
N = 600
p-value§
Female gender 34 27 33 0.12
Age 44 [41-48] 43 [41-47] 44 [41-47] 0.06
Born outside France 19 20 19 0.79
HIV transmission group 0.51
IV drug use 63 64 63
Heterosexual 16 12 15
Homosexual 10 14 11
Other or unknown 11 10 10
HCV genotype 0.48
1o r4 66 72 67
2o r3 18 25 20
5 101
Unknown 15 2 13
ASAT 47 [34-71] 52 [37-94] 48 [35-74] 0.06
ALAT 52 [35-84] 65 [42-91] 56 [35-87] 0.04
Previous exposure to IFN (not PEG) + ribavirine 9 9 9 0.95
Severe fibrosis (Metavir F3 or F4) 22 45 27 < 10
-3
Fibrosis score
F0-F1 59 40 55 < 10
-3
F2 18 16 18
F3 71 79
F4 15 28 18
CD4 < 200/mm
3 12 11 12 0.75
Undetectable HIV viral load 62 60 81 0.69
Antidepressants use 20 19 20 0.93
Harmful alcohol consumption
a 11 15 12 0.25
Daily cannabis use 15 18 16 0.52
Cocaine use 8 10 9 0.59
Heroin use 2 4 3 0.47
More than 20 cigarettes consumed per day 32 33 32 0.88
Depressive symptoms
b 40 41 40 0.80
Number of self-reported symptoms 7 [2-14] 6 [2-14] 7 [2-14] 0.53
Receiving ART 89 92 89 0.32
Number of years since first HIV positive test 17 [13-20] 16 [13-20] 17 [13-20] 0.11
Number of years since first HCV positive test 11 [7-15] 9 [4-13] 10 [6-15] 0.004
Patients negative beliefs HCV treatments
c 42 29 39 0.03
Patient- high adherence as perceived by the physician 38 47 40 0.10
Patient- alcohol problems as perceived by the physician 20 21 20 0.72
Patient- suicide attempts as reported by the physician 8 8 8 0.99
Patient- history of multiple treatments for depression as reported by the physician 19 20 19 0.77
Followed up by a general practitioner 22 39 26 0.001
Liver biopsy at enrolment 32 52 36 < 10
-3
a Defined as the consumption of more than 90 alcohol units/month for men and 60 alcohol units/month for women
b Patients were defined as having depressive symptoms if CES-D > 17 for men and > 23 for women
c Beliefs were measured on a 1-4 visual analogue scale. Believes HCV treatment to be non-effective (score 1) and associated with large number of side effects
(score 4)
§ A Chi-squared and T-test was performed for qualitative and quantitative variables respectively
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(1.04-1.23) per 10% increase) and the number of
patients enrolled in the cohort in each center (AOR
[95%CI]: 1.10 (1.02-1.18) per 10 patient increase), both
variables remained significantly associated with HCV
treatment initiation.
It is interesting to note that with respect to the other
patients, those receiving care in hospital from a general
practitioner working in an infectious diseases outpatient
clinic were more likely to present with severe liver fibro-
sis (37% vs. 23%, p = 0.003) and harmful alcohol con-
sumption (16% vs.8%, p = 0.007). Fewer were employed
(38% vs. 52%, p = 0.007). Furthermore, they were also
more likely to present with severe depressive symptoms
(30% vs. 22%, p = 0.05). These comparisons remained
significant even after controlling for inter-center varia-
bility using a mixed logistic regression model for each
outcome (liver fibrosis, harmful alcohol consumption,
employment, severe depressive symptoms).
Discussion
T h ep r e s e n ts t u d yc o n d u c t e di nal a r g ec o h o r to fH I V -
HCV infected patients enrolled and followed up in
France shows that barriers to HCV treatment do not
solely depend on patient characteristics and physicians’
perceptions of their patients. It highlights that patient
beliefs about HCV treatment can also significantly delay
HCV treatment initiation. The results suggest that gen-
eral practitioners working in hospitals play a major role
in engaging patients in HCV care. As expected and in
accordance with current guidelines for HCV treatment
prescription, we found that having a liver biopsy and
presenting with severe fibrosis remain major clinical
determinants of HCV treatment initiation. It is worth-
while noting that the study started when non-invasive
procedures had just become available and their sensitiv-
ity to detect advanced liver disease in co-infected was
n o tc o m p l e t e l yk n o w n .I ti sl i k e l yt h a tt h ea s s o c i a t i o n
found with having had a liver biopsy reflects common
hospital practices at the beginning of the cohort, so this
adjustment enables us to control for differential access
to liver biopsy.
These results remained valid after adjustment for age
and time since HCV diagnosis, which were both inver-
sely correlated with initiation of treatment.
Patients followed up by general practitioners working
in infectious diseases outpatient clinics were character-
ized by more severe liver fibrosis and reported signifi-
cantly higher levels of alcohol use than their
counterparts followed up by specialists. The former
were more likely to receive HCV treatment than the lat-
ter. This positive effect may be the result of an aware-
ness campaign for HCV treatment regularly conducted
by general practitioner-hospital networks. It could also
be the effect of a national campaign to fight HCV, con-
ducted among general practitioners in France between
1999 and 2002 [48]. Furthermore, there is a considerable
number of general practitioners involved in specialized
care networks for drug users. These same physicians are
often in charge, on a part-time basis, of following up
drug users in hospitals, and consequently provide more
comprehensive care for drug dependence, HIV and
HCV. It is also possible that the physicians in our study
had already met this group of patients with advanced
HCV disease and alcohol abuse in their private office
and subsequently convinced them to receive appropriate
clinical assessment and treatment for their HCV infec-
tion in the hospital outpatient clinics where they worked
as general practitioners. The fact that such patients had
severe fibrosis more frequently than others confirms
that their hospital based follow-up started when HCV
treatment was needed. Therefore, thanks to the link
between hospital services and general practitioners, hid-
den populations in France can be successfully engaged
in HCV care. In other settings, the creation of ad-hoc
multidisciplinary networkst oe n g a g ep a t i e n t si nH C V
treatment has also been found to be successful not only
in terms of access [25] but also in terms of response to
HCV treatment [26].
Qualitative research would be required to further
investigate the above hypotheses, as the survey instru-
ments and study design used here are limited.
This is the first quantitative study of coinfected HIV-
HCV individuals to highlight the association between
patients’ reduced access to HCV treatment and their
fear of both its ineffectiveness and side effects.
It is difficult to say to what extent such beliefs may
have been influenced by the information provided to
patients by their physicians, or by friends’ or relatives’
own experiences with HCV treatment. One survey con-
ducted among French drug users has already underlined
Figure 1 Distribution of patients according to the specialty of
their hospital physician.
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HCV treatment effectiveness and toxicity [24]. Other
qualitative and quantitative studies outside France have
confirmed the negative impact of opioid dependence
and/or negative perceptions about treatment on enga-
ging in HCV treatment [39,48-50]. In our study however
no significant association was found between reporting
such beliefs and opioid dependence. An association
between patients’ reluctance and engagement in HCV
treatment was found in another study [51] where 2 in 3
patients declined HCV treatment. It also confirms that
HCV treatment uptake is probably lower in HIV-HCV
co-infected patients, something already demonstrated in
previous research [52].
As the main concern of physicians involved in the
care of HIV-HCV co-infected patients is to maintain
high levels of adherence to ART, they may be reluctant
to add HCV treatment to ART due to the fear that side-
Table 2 Factors associated with HCV treatment initiation during the first three years of cohort follow-up; Univariate
and multivariate analyses based on a logistic regression model (n = 600, ANRS CO13 HEPAVIH cohort.)
Univariate analysis Multivariate analysis
p-value OR (95% CI) p-value AOR (95% CI)
Female gender
§ 0.12 0.70 (0.45-1.09)
Age
a§ 0.06 0.73 (0.52-1.01) 0.04 0.69 (0.48-0.98)
Born outside France
§ 0.81 1.06 (0.64-1.76)
Secondary school certificate
§ 0.84 1.04 (0.68-1.60)
Having children
§ 0.05 0.63 (0.40-0.99)
Living in a couple
§ 0.91 1.02 (0.69-1.52)
Steady partner
§ 0.57 1.13 (0.75-1.70)
Employment
§ 0.85 1.04 (0.70-1.54)
Owner or renter of their house
§ 0.24 0.68 (0.36-1.28)
Good housing conditions
b§ 0.53 1.19 (0.70-2.02)
Treated several times for depression
§ 0.97 0.99 (0.59-1.66)
Antidepressants use
§ 0.93 0.98 (0.59-1.61)
Harmful alcohol consumption
c§ 0.25 1.40 (0.79-2.50)
Daily cannabis use
§§ 0.57 1.18 (0.67-2.06)
Cocaine use
§§ 0.75 1.12 (0.55-2.27)
Heroin use
§§ 0.54 1.45 (0.44-4.77)
More than 20 cigarettes consumed a day
§§ 0.88 1.04 (0.67-1.59)
Depressive symptoms
d§ 0.96 1.01 (0.65-1.56)
Number of self-reported symptoms
§§ 0.53 0.99 (0.97-1.02)
Receiving ART
§ 0.32 1.43 (0.70-2.89)
Number of years since first HIV positive test
a 0.10 0.75 (0.53-1.06)
Number of years since first HCV positive test
a§§ 0.01 0.64 (0.47-0.88) 0.03 0.69 (0.49-0.97)
Patients negative perceptions about HCV treatment
§§e 0.03 0.60 (0.38-0.94) 0.02 0.58 (0.37-0.92)
Severe fibrosis
§f <1 0
-3 2.66 (1.74-4.09) < 10
-3 2.87 (1.83-4.51)
CD4 cell count < 200
§§ 0.89 0.95 (0.48-1.89)
Undetectable HIV viral load
§§ 0.69 1.09 (0.72-1.65)
Patient high adherence as perceived by the physician
§§ 0.21 1.30 (0.87-1.94)
Followed up by a general practitioner
§§ 0.01 1.93 (1.20-3.12) 0.03 1.71 (1.06-2.75)
Patient alcohol problems as reported by the physician
§§ 0.75 0.92 (0.53-1.57)
Patient suicide attempts as reported by the physician
§§ 0.99 1.01 (0.44-2.28)
Patient history of multiple treatments for depression as reported by the physician
§§ 0.77 1.09 (0.62-1.90)
Liver biopsy at enrolment < 10
-3 2.31 (1.54-3.45) < 10
-3 2.20 (1.44-3.35)
a Per ten year increase
b Good housing conditions were defined as ranks 3 and 4 (quite or very comfortable vs. uncomfortable or quite uncomfortable) using a four-point Likert scale
c Consumption of more than 90 alcohol units/month for men and 60 alcohol units/month for women
d Patients were defined as having depressive symptoms if CES-D > 17 for men and > 23 for women.
e Beliefs were measured on a 1-4 visual analogue scale. Believes HCV treatment to be non-effective (score 1) and associated with large number of side effects
(score 4)
f Severe fibrosis was defined according to Metavir score F3-F4 vs. F0-F1-F2.
§ < 5% of missing values estimated using multiple imputation
§§ < 10% of missing values estimated using multiple imputation
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mer [53,54] might compromise the effectiveness of the
latter. Nevertheless, recent data from the same cohort
have highlighted that adherence to ART is enhanced by
engagement in HCV treatment [55]. There is evidence
today to show that while individuals needing HCV treat-
ment often report not having enough information about
both its associated risks and benefits [17], they tend to
show much greater interest in commencing treatment
once informed [56]. Whatever the reason for this, our
findings underline the need to reduce barriers to HCV
treatment in this population by improving both the
patient-provider relationship and communication about
virological failure, side effects and their management
during HCV treatment.
As new anti-HCV drugs with increased efficacy and
better tolerance will soon be available, it is possible that
the fear of side-effects in this population may be attenu-
ated and that initiation of HCV treatment will increase
in HIV-HCV co-infected individuals.
Unlike what has been reported in the literature, we did
not find any significant association between HCV treat-
ment initiation and the following factors: physicians’
beliefs about patients’ adherence, alcohol abuse or opioid
dependence, patient self report of alcohol or drug use
[57]. This lack of association is probably attributable to
the more liberal guidelines available today regarding
access to HCV treatment. Although these same guide-
l i n e ss u g g e s tt h a tap a t i e n th a v ea“stabilized” lifestyle
before starting HCV treatment, they do not exclude drug
users or alcohol abusers from HCV treatment [11].
Nevertheless, alcohol abuse remains a major barrier to
treatment [58]. The lack of association between opioid
dependence and delay in HCV treatment in our study
may be related to changing perceptions by French HIV
physicians as they increasingly realize that opioid depen-
dence is not a limiting condition for sustained adherence,
even for life-long treatments like antiretrovirals [59].
Finally, factors directly related to HIV disease (such as
immune restoration) have also been shown to impact
patient HCV treatment uptake [28]. However, such
associations were not found in our study, possibly due
to the fact that most of our patients were receiving ART
and had good immune restoration.
Some limitations of the study need to be acknowl-
edged. Data on addictive behaviors were based on self-
reports, whose use is often questioned due to possible
social desirability bias. Nevertheless, the validity and
reliability of self-reports about substance use have been
established in many studies using similar methods for
data collection about addictive behaviors [60]. Moreover,
in France, the health insurance system allows even mar-
ginalized populations to have free access to care [61],
not only for HIV but also for drug dependence. That is
why we can presume that HIV-HCV co-infected patients
(including drug users) are adequately represented in the
sample.
The validity of the results is restricted to hospital-
based settings, yet many patients may be engaged in
HCV care in other settings (primary care, opioid substi-
tution treatment etc...).
In this analysis we were unable to account for specific
characteristics related to the model of HCV care used in
each hospital but it is important to point out that all
hospital centers were academic, urban and multidisci-
plinary. While another limitation could be the use of
various enrolment data as potential correlates of HCV
treatment initiation instead of time-varying factors, the
duration of the follow-up was so limited that it is unli-
kely that the correlates found could significantly change
over time.
It is also possible that the exclusion of patients already
treated (i.e. patients who were treated before follow-up),
may have hidden associations with other medical spe-
cialties among prescribing physicians. It is possible that
we focused on a selected population which has not yet
been treated for two main reasons: 1) not yet eligible for
HCV treatment according to current recommendations
or 2) because HCV treatment has been previously
delayed due to negative perception about their possible
treatment adherence or readiness to start. This could
potentially limit the external validity of the results
though we think that this study group reflects the reality
of patients currently needing treatment in countries with
similar guidelines and contexts.
Conclusions
Initiation of HCV treatment in France is related not
only to clinical characteristics, for example the severity
of liver fibrosis, but also to patients’ perceptions about
the effectiveness and constraints of this treatment and
to their relationship with their physicians. Hospital-pri-
mary care networks can play a crucial role in engaging
the most vulnerable patients and reducing inequities in
access to HCV care. Further operational research is
needed to assess to what extent these models can be
implemented in other settings and for patients who, like
HIV-HCV co-infected patients, bear the burden of living
with multiple co-morbidities.
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